8.4 Enzyme inhibition and activation

Enzyme Inhibition and Activation

Enzyme inhibition and activation control how fast enzyme-catalyzed reactions proceed. Molecules that bind to enzymes can either slow them down (inhibitors) or speed them up (activators), and the type of interaction determines exactly how the kinetic parameters change.

These concepts matter well beyond the classroom. Drug design relies heavily on enzyme inhibition, and understanding activation mechanisms is key to mapping metabolic regulation and signal transduction.

Types of Enzyme Inhibition

Three major types of reversible inhibition show up repeatedly in enzyme kinetics. Each one differs in where the inhibitor binds and what kinetic parameters it changes.

• Competitive inhibition occurs when an inhibitor binds directly to the enzyme's active site, competing with the substrate for the same binding pocket. The inhibitor structurally resembles the substrate, which is why it fits. A classic example is aspirin inhibiting cyclooxygenase (COX).
  • You can overcome competitive inhibition by flooding the system with substrate, since at high enough $[S]$, substrate molecules outcompete the inhibitor.
  • Kinetic effect: increases the apparent $K_m$ (the enzyme "appears" to have lower affinity for substrate) but leaves $V_{max}$ unchanged. If you add enough substrate, you still reach the same maximum velocity.
• Noncompetitive inhibition involves an inhibitor binding at an allosteric site (not the active site). Heavy metal ions poisoning enzymes are a common example. Because the inhibitor doesn't compete with substrate for the same site, adding more substrate won't help.
  • The inhibitor distorts the enzyme's conformation, reducing its ability to catalyze the reaction regardless of whether substrate is bound.
  • Kinetic effect: decreases $V_{max}$ (fewer functional enzyme molecules) but $K_m$ stays the same, since substrate binding affinity isn't affected.
• Uncompetitive inhibition is different from both: the inhibitor binds only to the enzyme-substrate (ES) complex, not to the free enzyme. This locks the enzyme in an unproductive state, preventing product release.
  • Kinetic effect: decreases both $V_{max}$ and $K_m$. The drop in $K_m$ might seem counterintuitive, but it happens because the inhibitor pulls the equilibrium toward ES complex formation, making the enzyme appear to bind substrate more tightly.
  • A commonly cited example is lithium's inhibition of certain phosphatases.

Effects on Enzyme Kinetics

The Michaelis-Menten equation describes the relationship between reaction velocity and substrate concentration:

$v = \frac{V_{max}[S]}{K_m + [S]}$

Here, $K_m$ is the substrate concentration at which $v$ equals half of $V_{max}$. A low $K_m$ means the enzyme has high affinity for its substrate (it reaches half-max speed at a low substrate concentration).

Each inhibition type alters this equation differently. For competitive inhibition, $K_m$ is replaced by an apparent value $K_m' = K_m(1 + \frac{[I]}{K_i})$, where $K_i$ is the inhibitor's dissociation constant. For noncompetitive inhibition, $V_{max}$ is replaced by $V_{max}' = \frac{V_{max}}{1 + \frac{[I]}{K_i}}$. Uncompetitive inhibition modifies both parameters by the same factor.

The Lineweaver-Burk plot (double reciprocal plot) linearizes the Michaelis-Menten equation to make inhibition types visually distinguishable:

$\frac{1}{v} = \frac{K_m}{V_{max}} \cdot \frac{1}{[S]} + \frac{1}{V_{max}}$

How to identify inhibition type from a Lineweaver-Burk plot:

1. Plot $\frac{1}{v}$ (y-axis) vs. $\frac{1}{[S]}$ (x-axis) for reactions with and without inhibitor.
2. Competitive: lines intersect on the y-axis (same $\frac{1}{V_{max}}$, different slopes).
3. Noncompetitive: lines intersect on the x-axis (same $\frac{-1}{K_m}$, different y-intercepts).
4. Uncompetitive: lines are parallel (both slope and intercepts change by the same factor).

Mechanisms of Enzyme Activation

Enzymes aren't just turned off by inhibitors; they're also turned on through several activation mechanisms.

• Allosteric activation: An activator molecule binds to an allosteric site and induces a conformational change that makes the active site more catalytically efficient. For example, AMP activates fructose-1,6-bisphosphatase as part of gluconeogenesis regulation. This mechanism allows metabolic pathways to respond dynamically to the cell's needs.
• Cofactor binding: Some enzymes are catalytically inactive without their cofactor. These can be metal ions or organic coenzymes that stabilize the enzyme's active conformation or participate directly in catalysis. Zinc is required for carbonic anhydrase activity, and $NAD^+$ is essential for dehydrogenases to carry out oxidation reactions.
• Phosphorylation: Kinase enzymes attach a phosphate group to specific amino acid residues (serine, threonine, or tyrosine) on a target enzyme. This covalent modification can either activate or deactivate the enzyme depending on the system. Glycogen phosphorylase, for instance, is activated by phosphorylase kinase. Phosphorylation is one of the most common regulatory switches in signal transduction.
• Proteolytic activation: Some enzymes are synthesized as inactive precursors called zymogens and only become active after a protease cleaves off a portion of the polypeptide chain. This is irreversible, unlike the other mechanisms above. Examples include pepsinogen → pepsin (in the stomach) and trypsinogen → trypsin (in the small intestine). Zymogens are a safety mechanism that prevents enzymes from digesting the tissues that produce them.

Inhibitors and Activators in Medicine

Enzyme inhibitors are among the most widely used drug classes. Here are some important examples and how they work:

• Statins (e.g., atorvastatin) competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. By blocking this step, statins lower blood cholesterol and reduce cardiovascular disease risk.
• Protease inhibitors (e.g., ritonavir) block HIV protease, preventing the virus from processing its polyproteins into functional components. This halts viral replication and is a cornerstone of antiretroviral therapy.
• Acetazolamide inhibits carbonic anhydrase, reducing bicarbonate and fluid production. It's used to treat glaucoma (by lowering intraocular pressure) and altitude sickness (by promoting respiratory compensation).
• Allopurinol inhibits xanthine oxidase, blocking the conversion of hypoxanthine and xanthine to uric acid. Lower uric acid levels prevent the crystal deposition that causes gout.

Enzyme activators also have clinical applications:

• Sulfonylureas (e.g., glimepiride) close ATP-sensitive potassium channels in pancreatic beta cells, which triggers depolarization and stimulates insulin secretion. They're used to manage type 2 diabetes.
• Benzodiazepines (e.g., diazepam) are positive allosteric modulators of $GABA_A$ receptors. They don't activate the receptor on their own but enhance the effect of GABA binding, producing sedative and anxiolytic effects.

In research, selective inhibitors and activators serve as tools to dissect enzyme function. Caspase inhibitors help study apoptosis pathways, kinase inhibitors are central to cancer biology research, and proteasome inhibitors reveal how cells manage protein degradation.